These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20040101)

  • 1. Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis.
    Xu Y; Wang Y; Tan Y; Zhang H; Wu L; Wang L; Hou Q; Zhang S
    BMC Microbiol; 2009 Dec; 9():274. PubMed ID: 20040101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.
    Queenan AM; Dowling DJ; Cheng WK; Faé K; Fernandez J; Flynn PJ; Joshi S; Brightman SE; Ramirez J; Serroyen J; Wiertsema S; Fortanier A; van den Dobbelsteen G; Levy O; Poolman J
    Vaccine; 2019 Jan; 37(1):80-89. PubMed ID: 30478007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
    Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
    Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007.
    Hallander H; Advani A; Alexander F; Gustafsson L; Ljungman M; Pratt C; Hall I; Gorringe AR
    Clin Vaccine Immunol; 2014 Feb; 21(2):165-73. PubMed ID: 24307240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection.
    Olivera N; Castuma CE; Hozbor D; Gaillard ME; Rumbo M; Gómez RM
    Biomed Res Int; 2014; 2014():421486. PubMed ID: 24982881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.
    Hallander HO; Ljungman M; Jahnmatz M; Storsaeter J; Nilsson L; Gustafsson L
    APMIS; 2009 Sep; 117(9):660-71. PubMed ID: 19703126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of recombinant and native pertactin of Bordetella pertussis.
    Xu Y; Zhang S; Bolgiano B; Tan Y; Asokanathan C; Zhang H; Xing D; Wang J
    Vaccine; 2011 Feb; 29(10):1974-80. PubMed ID: 21216309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
    Storsaeter J; Hallander HO; Gustafsson L; Olin P
    Vaccine; 1998 Dec; 16(20):1907-16. PubMed ID: 9796042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody responses to individual Bordetella pertussis fimbrial antigen Fim2 or Fim3 following immunization with the five-component acellular pertussis vaccine or to pertussis disease.
    Alexander F; Matheson M; Fry NK; Labram B; Gorringe AR
    Clin Vaccine Immunol; 2012 Nov; 19(11):1776-83. PubMed ID: 22956654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bordetella pertussis isolates in Finland: serotype and fimbrial expression.
    Heikkinen E; Xing DK; Olander RM; Hytönen J; Viljanen MK; Mertsola J; He Q
    BMC Microbiol; 2008 Sep; 8():162. PubMed ID: 18816412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.
    Cherry JD; Gornbein J; Heininger U; Stehr K
    Vaccine; 1998 Dec; 16(20):1901-6. PubMed ID: 9796041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection and humoral immune responses against Bordetella pertussis infection in mice immunized with acellular or cellular pertussis immunogens.
    van den Berg BM; David S; Beekhuizen H; Mooi FR; van Furth R
    Vaccine; 2000 Dec; 19(9-10):1118-28. PubMed ID: 11137247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice.
    Orr B; Douce G; Baillie S; Parton R; Coote J
    Vaccine; 2007 Jan; 25(1):64-71. PubMed ID: 16916566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of pertactin in pertussis vaccines: the jury is still out.
    Desauziers E; Danve B; Decker MD; Veitch K
    J Infect Dis; 2004 Apr; 189(7):1332-3; author reply 1333-5. PubMed ID: 15031804
    [No Abstract]   [Full Text] [Related]  

  • 15. Crucial role of antibodies to pertactin in Bordetella pertussis immunity.
    Hellwig SM; Rodriguez ME; Berbers GA; van de Winkel JG; Mooi FR
    J Infect Dis; 2003 Sep; 188(5):738-42. PubMed ID: 12934190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertussis Vaccine Candidate Based on Outer Membrane Vesicles Derived From Biofilm Culture.
    Carriquiriborde F; Martin Aispuro P; Ambrosis N; Zurita E; Bottero D; Gaillard ME; Castuma C; Rudi E; Lodeiro A; Hozbor DF
    Front Immunol; 2021; 12():730434. PubMed ID: 34603306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small mutations in Bordetella pertussis are associated with selective sweeps.
    van Gent M; Bart MJ; van der Heide HG; Heuvelman KJ; Mooi FR
    PLoS One; 2012; 7(9):e46407. PubMed ID: 23029513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine.
    Hegerle N; Dore G; Guiso N
    Vaccine; 2014 Nov; 32(49):6597-600. PubMed ID: 25312274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertussis vaccine: a critique.
    Robbins JB; Schneerson R; Keith JM; Miller MA; Kubler-Kielb J; Trollfors B
    Pediatr Infect Dis J; 2009 Mar; 28(3):237-41. PubMed ID: 19165133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bordetella pertussis pertactin knock-out strains reveal immunomodulatory properties of this virulence factor.
    Hovingh ES; Mariman R; Solans L; Hijdra D; Hamstra HJ; Jongerius I; van Gent M; Mooi F; Locht C; Pinelli E
    Emerg Microbes Infect; 2018 Mar; 7(1):39. PubMed ID: 29559630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.